A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-sma
A phase 3 trial of Sevabertinib, Pembrolizumab, Cisplatin in non-small-cell lung cancer and small-cell lung cancer, run by Bayer, now recruiting.
Overview
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) is a phase 3 interventional study registered as NCT06452277 by Bayer, with 444 participants planned, started 2024-08-28 and due to reach its primary completion in 2027-10-28. Interventions recorded: Sevabertinib, Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed. Conditions listed: Advanced Non-small Cell Lung Cancer, HER2 Mutation. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialA Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous N
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialA Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic N
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialDatopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialA Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous N
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialA Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialA Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Par
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.
- TrialA Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip
Shares Pemetrexed, Cisplatin, Carboplatin, Pembrolizumab.